<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760758</url>
  </required_header>
  <id_info>
    <org_study_id>CDI-31244-P1-001</org_study_id>
    <nct_id>NCT02760758</nct_id>
  </id_info>
  <brief_title>A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects</brief_title>
  <official_title>A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cocrystal Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cocrystal Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor
      (NNI) in healthy volunteers and HCV infected individuals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, double-blind, placebo-controlled, randomized, single ascending oral
      dose and multiple oral dose design, incorporating fed/fasted comparisons.

      The study will include two groups: Group A - single ascending dose (SAD) including a food
      effect cohort, and multiple dose (MD) in healthy volunteers (HV), and Group B MD in Hepatitis
      C Virus (HCV) infected individuals divided in two parts.

      Five single-dose cohort are planned. For the five single-dose cohorts, a sentinel group of 2
      subjects will be dosed at least one day prior to enrolling remaining subjects.

      Six multiple-dose cohorts are planned. Three multiple dose cohorts in healthy volunteers and
      three cohorts in HCV-infected individuals.

      The dosing of Group B will be conducted following safety and pharmacokinetic (PK) review of
      Group A. The dosing of Group B, Part 2 will be conducted only if Part 1 shows acceptable
      safety and efficacy results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (AE)</measure>
    <time_frame>Day 1 to Day 35</time_frame>
    <description>The safety and the tolerability of single and multiple oral doses of CDI-31244 through number of AEs observed in HV and HCV infected subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure plasma levels of CDI-31244 after SD</measure>
    <time_frame>Day 1 to Day 6</time_frame>
    <description>Plasma levels of CDI-31244 in the the single dose HV cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure plasma levels of CDI-31244 after SD in fasted and fed conditions</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <description>The effect of food on the plasma levels of CDI-31244 in the single dose HV cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure plasma levels of CDI-31244 after MD</measure>
    <time_frame>Day 1 to Day 13</time_frame>
    <description>Plasma levels of CDI-31244 in the multiple dose HV and HCV infected cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure HCV viral load through the RNA quantitative test</measure>
    <time_frame>Day 1 to Day 35</time_frame>
    <description>The clinical efficacy of CDI-31244 in HCV-infected subjects as measured by the maximal change in antiviral activity through changes in the HCV RNA load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure HCV mutation through genotyping at baseline and after CDI-31244 dosing</measure>
    <time_frame>Day 1 to 35</time_frame>
    <description>The possible emergence of hepatitis C virus resistance mutation in HCV infected subjects</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Cohort 1A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 20 mg active or placebo single dose (SD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 50 mg active or placebo SD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 100 mg active or placebo SD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 200 mg active or placebo SD; food effect</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 400 mg active or placebo SD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 200 mg active or placebo multiple dose (MD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 200 mg active or placebo MD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8A HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 400 mg active or placebo MD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B HCV genotype (GT) 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 400 mg active or placebo MD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B HCV GT 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 600 mg active or placebo MD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B HCV GT 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDI-31244 800 mg active or placebo MD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDI-31244</intervention_name>
    <description>NNI</description>
    <arm_group_label>Cohort 1A HV</arm_group_label>
    <arm_group_label>Cohort 2A HV</arm_group_label>
    <arm_group_label>Cohort 3A HV</arm_group_label>
    <arm_group_label>Cohort 4A HV</arm_group_label>
    <arm_group_label>Cohort 5A HV</arm_group_label>
    <arm_group_label>Cohort 6A HV</arm_group_label>
    <arm_group_label>Cohort 7A HV</arm_group_label>
    <arm_group_label>Cohort 1B HCV genotype (GT) 1</arm_group_label>
    <arm_group_label>Cohort 2B HCV GT 1</arm_group_label>
    <arm_group_label>Cohort 3B HCV GT 1</arm_group_label>
    <arm_group_label>Cohort 8A HV</arm_group_label>
    <other_name>CC-31244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>no active ingredients</description>
    <arm_group_label>Cohort 1A HV</arm_group_label>
    <arm_group_label>Cohort 2A HV</arm_group_label>
    <arm_group_label>Cohort 3A HV</arm_group_label>
    <arm_group_label>Cohort 4A HV</arm_group_label>
    <arm_group_label>Cohort 5A HV</arm_group_label>
    <arm_group_label>Cohort 6A HV</arm_group_label>
    <arm_group_label>Cohort 7A HV</arm_group_label>
    <arm_group_label>Cohort 1B HCV genotype (GT) 1</arm_group_label>
    <arm_group_label>Cohort 2B HCV GT 1</arm_group_label>
    <arm_group_label>Cohort 3B HCV GT 1</arm_group_label>
    <arm_group_label>Cohort 8A HV</arm_group_label>
    <other_name>CDI-31244 Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Male or female aged ≥ 18 to ≤ 65 years;

          -  Body mass index ≥ 18.5 to ≤ 35.0 kg/m2;

          -  Body weight ≥ 50 kg;

          -  Negative screening for alcohol and drugs of abuse;

          -  Normal results on 12-lead electrocardiogram (ECG);

          -  For females, negative result on a pregnancy test.

        HCV INFECTED SUBJECTS:

          -  HCV treatment-naïve subjects must have not received prior direct acting agent (DAA)
             treatment for hepatitis C infection;

          -  Documented clinical history compatible with chronic hepatitis C;

          -  HCV Genotype 1 by HCV genotyping performed at Screening;

          -  Plasma HCV RNA ≥ 5.0 log10 IU/mL at Screening;

          -  Laboratory evidence of no cirrhosis (negative liver biopsy or fibroscan or FibroTest,
             F2 or lower) within one year prior to study), if these are not available, do a
             FibroTest at screening, which must be F2 or lower.

        Main Exclusion Criteria:

        HV and HCV INFECTED SUBJECTS:

          -  Females who are pregnant or are lactating;

          -  Co-infected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency
             virus (HIV);

          -  Abuse of alcohol and/or drugs that could interfere with adherence to study
             requirements as judged by the investigator;

          -  Positive screen result for drugs of abuse or alcohol on Day -1. Use of other
             investigational drugs within 60 days of dosing;

          -  Subject with intestinal malabsorption;

          -  Presence of out-of-range cardiac interval on the screening ECG or other clinically
             significant ECG abnormalities;

          -  Serum creatinine &gt; upper limit of normal (ULN);

          -  Any clinically significant medical condition that, in the opinion of the investigator,
             would jeopardize the safety of the subject or impact the validity of the study
             results.

        HEALTHY VOLUNTEERS:

          -  Positive screen for anti-HCV antibody

        HCV INFECTED SUBJECTS:

          -  Clinical (in the opinion of the investigator) or laboratory evidence of cirrhosis;

          -  History or signs of decompensated liver disease: ascites, variceal bleeding, hepatic
             encephalopathy, spontaneous bacterial peritonitis, or other clinical signs of portal
             hypertension or hepatic insufficiency;

          -  History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC;

          -  Active clinically significant diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Pattassery</last_name>
    <role>Study Director</role>
    <affiliation>Cocrystal Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-nucleoside inhibitor</keyword>
  <keyword>NNI</keyword>
  <keyword>HCV</keyword>
  <keyword>DAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

